WallStSmart

Boston Scientific Corp (BSX)vsCanadian Natural Resources Ltd (CNQ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Canadian Natural Resources Ltd generates 93% more annual revenue ($38.76B vs $20.07B). CNQ leads profitability with a 27.9% profit margin vs 14.4%. BSX appears more attractively valued with a PEG of 0.75. CNQ earns a higher WallStSmart Score of 67/100 (B-).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

CNQ

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+2.0%)

Margin of Safety

+2.0%

Fair Value

$70.62

Current Price

$69.17

$1.45 discount

UndervaluedFair: $70.62Overvalued
CNQUndervalued (+76.8%)

Margin of Safety

+76.8%

Fair Value

$175.50

Current Price

$50.09

$125.41 discount

UndervaluedFair: $175.50Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

CNQ6 strengths · Avg: 9.2/10
Revenue GrowthGrowth
150.0%10/10

Revenue surging 150.0% year-over-year

EPS GrowthGrowth
372.3%10/10

Earnings expanding 372.3% YoY

Market CapQuality
$101.52B9/10

Large-cap with strong market position

Return on EquityProfitability
25.8%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.9%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
13.0x8/10

Attractively priced relative to earnings

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

CNQ1 concerns · Avg: 2.0/10
PEG RatioValuation
3.422/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : CNQ

The strongest argument for CNQ centers on Revenue Growth, EPS Growth, Market Cap. Profitability is solid with margins at 27.9% and operating margin at 19.6%. Revenue growth of 150.0% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : CNQ

The primary concerns for CNQ are PEG Ratio.

Key Dynamics to Monitor

CNQ carries more volatility with a beta of 1.06 — expect wider price swings.

CNQ is growing revenue faster at 150.0% — sustainability is the question.

CNQ generates stronger free cash flow (2.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CNQ scores higher overall (67/100 vs 63/100), backed by strong 27.9% margins and 150.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Canadian Natural Resources Ltd

ENERGY · OIL & GAS E&P · USA

Canadian Natural Resources Limited acquires, explores, develops, produces, markets and sells crude oil, natural gas and natural gas liquids (NGL). The company is headquartered in Calgary, Canada.

Want to dig deeper into these stocks?